425 related articles for article (PubMed ID: 23983273)
1. Chronic Pseudomonas aeruginosa infection and respiratory muscle impairment in cystic fibrosis.
Dassios TG; Katelari A; Doudounakis S; Dimitriou G
Respir Care; 2014 Mar; 59(3):363-70. PubMed ID: 23983273
[TBL] [Abstract][Full Text] [Related]
2. Respiratory muscle function in patients with cystic fibrosis.
Dassios T; Katelari A; Doudounakis S; Mantagos S; Dimitriou G
Pediatr Pulmonol; 2013 Sep; 48(9):865-73. PubMed ID: 23143864
[TBL] [Abstract][Full Text] [Related]
3. Aerobic exercise and respiratory muscle strength in patients with cystic fibrosis.
Dassios T; Katelari A; Doudounakis S; Dimitriou G
Respir Med; 2013 May; 107(5):684-90. PubMed ID: 23485096
[TBL] [Abstract][Full Text] [Related]
4. Maximum rate of pressure development and maximal relaxation rate of respiratory muscles in patients with cystic fibrosis.
Dassios TG; Doudounakis S; Dimitriou G
Respir Care; 2013 Mar; 58(3):474-81. PubMed ID: 22781492
[TBL] [Abstract][Full Text] [Related]
5. Inspiratory Muscle Strength and Endurance in Children and Adolescents with Cystic Fibrosis.
Vendrusculo FM; Heinzmann-Filho JP; Piva TC; Marostica PJ; Donadio MV
Respir Care; 2016 Feb; 61(2):184-91. PubMed ID: 26604327
[TBL] [Abstract][Full Text] [Related]
6. Impact of Pseudomonas aeruginosa Infection on Respiratory Muscle Function in Adult Cystic Fibrosis Patients.
Magnet FS; Callegari J; Dieninghoff D; Spielmanns M; Storre JH; Schmoor C; Windisch W
Respiration; 2017; 93(1):42-50. PubMed ID: 27875809
[TBL] [Abstract][Full Text] [Related]
7. Timing and driving components of the breathing strategy in children with cystic fibrosis during exercise.
Keochkerian D; Chlif M; Delanaud S; Gauthier R; Maingourd Y; Ahmaidi S
Pediatr Pulmonol; 2005 Nov; 40(5):449-56. PubMed ID: 16163725
[TBL] [Abstract][Full Text] [Related]
8. Muscle impairment in neuromuscular disease using an expiratory/inspiratory pressure ratio.
Fregonezi G; Azevedo IG; Resqueti VR; De Andrade AD; Gualdi LP; Aliverti A; Dourado-Junior ME; Parreira VF
Respir Care; 2015 Apr; 60(4):533-9. PubMed ID: 25587161
[TBL] [Abstract][Full Text] [Related]
9. Inspiratory muscle training in patients with cystic fibrosis.
de Jong W; van Aalderen WM; Kraan J; Koëter GH; van der Schans CP
Respir Med; 2001 Jan; 95(1):31-6. PubMed ID: 11207014
[TBL] [Abstract][Full Text] [Related]
10. The effects of chronic hyperinflation, nutritional status, and posture on respiratory muscle strength in cystic fibrosis.
O'Neill S; Leahy F; Pasterkamp H; Tal A
Am Rev Respir Dis; 1983 Dec; 128(6):1051-4. PubMed ID: 6650979
[TBL] [Abstract][Full Text] [Related]
11. Factors associated with FEV1 decline in cystic fibrosis: analysis of the ECFS patient registry.
Kerem E; Viviani L; Zolin A; MacNeill S; Hatziagorou E; Ellemunter H; Drevinek P; Gulmans V; Krivec U; Olesen H;
Eur Respir J; 2014 Jan; 43(1):125-33. PubMed ID: 23598952
[TBL] [Abstract][Full Text] [Related]
12. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
Hansen CR; Pressler T; Høiby N
J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
[TBL] [Abstract][Full Text] [Related]
13. Mucus removal is impaired in children with cystic fibrosis who have been infected by Pseudomonas aeruginosa.
Laube BL; Sharpless G; Benson J; Carson KA; Mogayzel PJ
J Pediatr; 2014 Apr; 164(4):839-45. PubMed ID: 24373575
[TBL] [Abstract][Full Text] [Related]
14. Regulatory T-cell impairment in cystic fibrosis patients with chronic pseudomonas infection.
Hector A; Schäfer H; Pöschel S; Fischer A; Fritzsching B; Ralhan A; Carevic M; Öz H; Zundel S; Hogardt M; Bakele M; Rieber N; Riethmueller J; Graepler-Mainka U; Stahl M; Bender A; Frick JS; Mall M; Hartl D
Am J Respir Crit Care Med; 2015 Apr; 191(8):914-23. PubMed ID: 25632992
[TBL] [Abstract][Full Text] [Related]
15. [Indirect evaluation of respiratory muscle strength with the help of markers of maximal inspiratory and expiratory pressure in the mouth of healthy individuals].
Adamiak-Kardas M
Pol Merkur Lekarski; 2002 Mar; 12(69):178-80. PubMed ID: 12053582
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.
Nixon GM; Armstrong DS; Carzino R; Carlin JB; Olinsky A; Robertson CF; Grimwood K
J Pediatr; 2001 May; 138(5):699-704. PubMed ID: 11343046
[TBL] [Abstract][Full Text] [Related]
17. Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.
Li Z; Kosorok MR; Farrell PM; Laxova A; West SE; Green CG; Collins J; Rock MJ; Splaingard ML
JAMA; 2005 Feb; 293(5):581-8. PubMed ID: 15687313
[TBL] [Abstract][Full Text] [Related]
18. Proximity to blue spaces and risk of infection with Pseudomonas aeruginosa in cystic fibrosis: A case-control analysis.
Goeminne PC; Nawrot TS; De Boeck K; Nemery B; Dupont LJ
J Cyst Fibros; 2015 Nov; 14(6):741-7. PubMed ID: 25940953
[TBL] [Abstract][Full Text] [Related]
19. Early eradication therapy against Pseudomonas aeruginosa in cystic fibrosis patients.
Taccetti G; Campana S; Festini F; Mascherini M; Döring G
Eur Respir J; 2005 Sep; 26(3):458-61. PubMed ID: 16135728
[TBL] [Abstract][Full Text] [Related]
20. Effects of pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis.
Pamukcu A; Bush A; Buchdahl R
Pediatr Pulmonol; 1995 Jan; 19(1):10-5. PubMed ID: 7675552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
